Novavax Advances Development of Novel COVID-19 Vaccine
Vaccine candidate derived from coronavirus spike (S) protein
Matrix-M™ adjuvant expected to boost immune responses
Phase 1 clinical trial planned for late spring
GAITHERSBURG, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its efforts to develop a novel vaccine to protect against coronavirus disease COVID-19. Novavax has produced and is currently assessing multiple nanoparticle vaccine candidates in animal models prior to identifying an optimal candidate for human testing, which is expected to begin by the end of spring 2020.
Novavax created the COVID-19 vaccine candidates using its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidate to enhance immune responses.
“Our previous experience working with other corona viruses, including both MERS and SARS, allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Now that the protein has been expressed stably in our baculovirus system, we aim to identify the optimal candidate and scale up production of sufficient vaccine for preliminary clinical trials. We are now well-positioned to advance the COVID-19 vaccine candidate to Phase I clinical testing in May or June.”
Novavax has a proven track record of rapid innovative vaccine development against novel emerging viruses, including efforts to develop vaccines against previous coronaviruses, Middle East Respiratory Syndrome (MERS-CoV), and Severe Acute Respiratory Syndrome (SARS). In both cases, Novavax’ candidate vaccines demonstrated strong immunogenicity and 100% protection against virus challenge in preclinical testing. Novavax also developed a safe and clinically immogenetic Ebola vaccine candidate that proved effective in primate studies.
About Coronaviruses
A new strain of coronavirus first appeared in late 2019 in China before beginning its rapid spread across the globe. The disease, named COVID-19, continues to cause severe pneumonia-like symptoms in many of those infected. Coronaviruses, so named for their “crown-like” appearance, are a large family of viruses that spread from animals to humans and include diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) in addition to COVID-19. While much remains unknown about the new coronavirus, it is known that the virus can spread via human-to-human transmission before any symptoms appear.
About Matrix-M™
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune responses.
About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract infection, which is the second leading cause of death in children under one year of age worldwide. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including those regarding the potential for NanoFlu to offer broadly protective immunity and improved vaccine efficacy, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Bueno, Seguidor, espero que esto te deje un poco más tranquilo. Hoy habla Trump por la noche. Puede que con el mercado cerrado. Comparece para hablar del Coronavirus con gente de CDC y del HHS. Eso puede ser una inyección tremenda porque va a hablar de las medidas del Gobierno para controlar el estallido de la enfermedad. Y una de las claves pasa por las vacunas. Y ahí está Novavax.
Anda que si por una vez Stan y compañía aciertan con el Timing de las cosas..... 🤔🤔🤔
#9983
Re: Novavax (NVAX): Un Nuevo Comienzo
Pues a volar, haber si llegamos al antiguo 1 dólar antes de la publicación del nonoflu. Desde el punto de vista psicológico, y si estuviéramos cotizando con el anterior precio... no se vería tan difícil llegar.
Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....
#9985
Nova as - Novavax (NVAX) - Novavax (NVAX)
Nuevo
Sabéis este meneo de hoy a qué se debe
#9986
Re: Novavax (NVAX): Un Nuevo Comienzo
Para los que controlais de técnico y Nasdaq, han distribuido de lo lindo no? La vela que esta dejando es de lo más feo que he visto en el tiempo que llevo en esto, veis que pueda remontar durante la sesión como la última subida a 10 que cerró en máximos o hoy esta el pescado vendido y damos gracias con no cerrar en rojo?
#9987
Re: Novavax (NVAX): Un Nuevo Comienzo
Esto lo recuperamos en seguida hombre. Como dijo ayer mismo patoulax la anterior gran subida se inició con la fase I de otro fármaco/vacuna. Si se acerca al gap yo sumaré otras más pero no creo que baje hasta ahí. Ahora, poco caso a mí que de experto tengo poco o nada. ¡Suerte!
Para la vela diaria es temprano aún, a saber cómo acabará, En horario no parece que tenga mucho que ver con la anterior subida, y ese 40% de subida en la primera media hora de sesión no era moco de pavo, los que andábamos dentro se le ha podido sacar partido, quizás al 40% no pero muchas posibilidades antes y después de el. Pienso que se ha subido el siguiente escalón, y espero que la zona de 9 la consolide como soporte. Ahora mismo, esa vela no va teniendo la misma pinta eh??
Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....
#9989
Re: Novavax (NVAX): Un Nuevo Comienzo
Hay que tener paciencia si y a ver como cierra hoy y la semana y el mes, que la mensual puede ser bonita. Me metí por la divergencia en semanal y se tiene que empezar a notar ahora, pero como el técnico no siempre se impone pues....da respeto, pero no me bajo aun ni mucho menos, y menos no teniendo gráfico delante. Gracias por las respuestas chicos.
